Analysts Set Kenvue Inc. (NYSE:KVUE) Target Price at $22.64

Shares of Kenvue Inc. (NYSE:KVUE) have been given a consensus rating of “Hold” by the twelve brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $22.64.

Several analysts have weighed in on the company. JPMorgan Chase & Co. lifted their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Jefferies Financial Group began coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target on the stock. Finally, Bank of America increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd.

Institutional Investors Weigh In On Kenvue

Several large investors have recently modified their holdings of the stock. Riverview Trust Co acquired a new stake in shares of Kenvue during the third quarter worth $30,000. Ashton Thomas Securities LLC purchased a new stake in Kenvue during the third quarter valued at about $35,000. Studio Investment Management LLC lifted its stake in Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after buying an additional 845 shares in the last quarter. Deseret Mutual Benefit Administrators boosted its holdings in shares of Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after buying an additional 651 shares during the period. Finally, Brooklyn Investment Group purchased a new position in shares of Kenvue in the third quarter worth approximately $71,000. 97.64% of the stock is owned by institutional investors.

Kenvue Trading Down 0.9 %

Shares of NYSE:KVUE opened at $21.53 on Wednesday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company’s 50-day moving average price is $22.96 and its 200 day moving average price is $21.43. The company has a market cap of $41.28 billion, a PE ratio of 39.15, a P/E/G ratio of 2.02 and a beta of 1.36. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Kenvue’s revenue was down .4% compared to the same quarter last year. During the same quarter last year, the business earned $0.31 earnings per share. Sell-side analysts anticipate that Kenvue will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.81%. The ex-dividend date was Wednesday, November 13th. Kenvue’s payout ratio is 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.